Boehringer kicks off clinical obesity programme for triple agonist
01 Jul 2024
Boehringer Ingelheim and partner Gubra on Monday launched a Phase I study of experimental obesity treatment BI 3034701, the second weight-loss candidate from the partners to enter the clinic.
In the announcement, BI 3034701 is described as a “long-acting triple agonist peptide” with first-in-class potential.
The German drugmaker did not respond to an inquiry regarding whether the candidate acts on the same three receptors as Eli Lilly’s weight-loss therapy retatrutide, commonly referred to as a “triple G” agonist because it targets GLP-1, GIP, and glucagon. Last year, retatrutide set the triple agonism standard by demonstrating an average weight loss of about 24% in a Phase II trial.
Weight loss pipeline
The Phase I study of BI 3034701 is expected to enrol 124 participants and will be divided into two parts. The first half will recruit healthy men between the ages of 18 and 55 to establish the candidate’s safety, and the second portion will administer several subcutaneous doses of the experimental treatment to individuals between 18 and 65 years old with overweight or obesity who are otherwise healthy.
The trial is expected to wrap up in the second half of 2025.
The study launch triggered an undisclosed milestone payment to Gubra, who has now helped bring two obesity candidates to the clinic with Boehringer. Last year, the partners kicked off a Phase I study of BI 1820237, a long-acting NPY2 agonist.
Boehringer’s most advanced weight loss hopeful is survodutide, a glucagon/GLP-1 receptor dual agonistglucagon/GLP-1 receptor dual agonist it’s co-developing with Zealand. While Phase II data released last year showed that the candidate achieved about 19% weight loss in patients at 46 weeks, nearly a quarter of participants who received the investigational treatment dropped out due to gastrointestinal adverse events. For more analysis, see ADA23: Tolerability clouds Boehringer, Zealand Pharma's obesity ambitions for survodutide.
Despite the tolerability concerns, the pair moved survodutide into a Phase III trial last August. The candidate is also in Phase III testing for metabolic dysfunction-associated steatohepatitis (MASH).
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.